Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TMVP1-ICG for SLN Mapping in Cervical Cancer
NCT03320772Phase 1Unknown
- Sponsor
- Huazhong University of Science and Technology
- Start
- May 2017
- Primary completion
- May 2018
- Modality
- Light/Condition-Responsive Prodrugs, Peptide-Drug Conjugates
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of TMVP1-ICG in Cervical Cancer (CC) (2 arms), sponsored by Huazhong University of Science and Technology. Primary endpoint: Detection rate of sentinel lymph node at 1 day. Status: unknown.
02
Drugs
TMVP1-ICG
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT03320772.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03320772.